Scalper1 News
Jazz Pharmaceuticals shares fell late Tuesday after the drugmaker topped fourth-quarter estimates but guided 2015 revenue and profit below views. That followed United Therapeutics (UTHR), which also logged better-than-expected Q4 results. Jazz (JAZZ) earned $2.44 a share excluding a variety of items, up 42% a year earlier and 14 cents above consensus estimates. Revenue gained 39% to $328.1 million vs. views for $319.1 million. Scalper1 News
Scalper1 News